1.MicroRNAs regulate epithelial-mesenchymal transition of supraglottic laryngeal cancer.
Jun TAI ; Xiao XIAO ; Zhi-gang HUANG ; Zhen-kun YU ; Xiao-hong CHEN ; Wei-guo ZHOU ; Xue-jun CHEN ; Yuan-sheng RAO ; Ju-gao FANG ; Xin NI
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2013;48(6):499-503
OBJECTIVETo study microRNAs (miRNAs) expression profiles associated with epithelial-mesenchymal transition (EMT) in lymph node metastasis of supraglottic laryngeal squamous cell carcinomas(SGLSCC).
METHODSPrimary tumor tissue samples of 12 SGLSCC patients were collected, including 6 patients clinically diagnosed with lymph nodes metastasis (N(+)) and 6 patients with lymph nodes metastasis-free (N0), for miRNA microarray gene-expression profiling to identify the differences between N(+) and N0 groups. Differentially expressed miRNAs was verified using quantitative real-time PCR in 20 patients with N(+) and 20 patients with N0. Target genes for the miRNAs associated with EMT in SGLSCC metastasis were analyzed.
RESULTSTen miRNAs differentially expressed between N(+) group and N0 group were determined. Comparing with N0 group, nine miRNAs were over-expressed and one miRNA was expressed at lower level in N(+) group. The genes for miR-192, miR-143, miR-409 and miR-634 were predicted as target genes that could promote EMT of laryngeal cancer cells by targeted inhibiting Krüppel-like factor 17(KLF17), E-cadherin and phosphatidylinositol 3 kinase (PI3K).
CONCLUSIONSThe miRNAs over-expressed in group N(+) can be used to predict cervical lymph node metastasis in SGLSCC. The miRNAs as new markers could improve the diagnosis and treatment of SGLSCC.
Aged ; Cadherins ; Carcinoma, Squamous Cell ; genetics ; metabolism ; Epithelial-Mesenchymal Transition ; physiology ; Gene Expression Profiling ; Head and Neck Neoplasms ; genetics ; metabolism ; Humans ; Laryngeal Neoplasms ; genetics ; metabolism ; Larynx ; Larynx, Artificial ; Lymph Nodes ; Lymphatic Metastasis ; genetics ; MicroRNAs ; metabolism ; Phosphatidylinositol 3-Kinases ; metabolism
2.The anti-HIV activity of three 2-alkylsulfanyl-6-benzyl-3, 4-dihydropyrimidin-4 (3H)-one derivatives acting as non-nucleoside reverse transcriptase inhibitor in vitro.
Jing LONG ; De-hua ZHANG ; Gao-hong ZHANG ; Zhi-kun RAO ; Yun-hua WANG ; Siu-cheung TAM ; Yan-ping HE ; Yong-tang ZHENG
Acta Pharmaceutica Sinica 2010;45(2):228-234
It was recently shown that several new synthetic 2-alkylsulfanyl-6-benzyl-3, 4-dihydropyrimidin-4(3H)-one (S-DABO) derivatives demonstrated anti-HIV-1 activity. Three of the derivatives namely RZK-4, RZK-5 and RZK-6 were used in this study to explore their inhibitory effects on a variety of HIV strains. These compounds at a concentration of 200 microg mL(-1) almost completely inhibited the activity of recombinant HIV-1 reverse transcriptase. All of the three compounds reduced replication of HIV-1 laboratory-derived strains, low-passage clinical isolated strain, and the drug resistant strain. In particular RZK-6 showed potent activity against the HIV-1 drug resistant strain. In general, the antiviral activities are similar in magnitude to nevirapine (NVP), which is a non-nucleoside reverse transcriptase inhibitor approved by FDA. The therapeutic indexes of these compounds were remarkable, ranging from 3704 to 38462 indicating extremely low cytotoxicity. These results suggest that the three S-DABO derivatives in this study have good potential for further development in anti-HIV-1 therapy. It may be particularly useful to target at the non-nucleoside reverse transcriptase inhibitors resistant HIV-1 strain.
Anti-HIV Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
Benzyl Compounds
;
chemical synthesis
;
chemistry
;
pharmacology
;
Cell Line
;
Drug Resistance, Viral
;
HIV Reverse Transcriptase
;
antagonists & inhibitors
;
metabolism
;
HIV-1
;
drug effects
;
Humans
;
Pyrimidinones
;
chemical synthesis
;
chemistry
;
pharmacology
;
Reverse Transcriptase Inhibitors
;
chemical synthesis
;
chemistry
;
pharmacology
;
Virus Replication
;
drug effects
3.Correlation between phonetically balanced maximum and pure tone auditory threshold among 106 auditory neuropathy patients.
Lan LAN ; Dong-Yi HAN ; Wei SHI ; Ming-Kun HAN ; Qiong LIU ; Hai-Na DING ; Zhi-Hui CHEN ; Da-Yong WANG ; Shan-Hong LI ; Ming-Li GUO ; Shao-Qi RAO ; Qiu-Ju WANG
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2008;43(5):341-346
OBJECTIVETo estimate correlation between phonetically balanced maximum (PB max) and pure tone auditory threshold in auditory neuropathy (AN) patients.
METHODSOne hundred and six AN patients were identified using multiple criteria including PB max, a metric for speech recognition, pure tone auditory threshold, acoustic emission test, distortion products otoacoustic emission (DPOAE) and auditory brainstem response (ABR). SPSS statistical software was used to estimate the Pearson's correlation between PB max and pure tone auditory threshold and to test whether pure tone auditory threshold, or auditory configuration had a significant impact on PB max.
RESULTSEven the patients had the same or similar values for pure tone auditory threshold or auditory configuration, varied values of PB max were found in two hundreds and twelve ears for 106 patients. Analysis of the data for 106 patients revealed a negative correlation (r = -0. 602, P <0. 01) between PB max and pure tone auditory threshold, i. e. hearing loss at a mild relates to a lower PB max. By using analysis of variance (ANOVA) method, it was found that both pure tone auditory threshold and auditory configuration had a significant (P <0.01) impact on the patients' PB max.
CONCLUSIONSThis analysis implicated the promise and potential of pure tone auditory threshold and auditory configuration for predicting PB max of the AN patients, and improving the diagnosis of AN.
Adolescent ; Adult ; Audiometry, Pure-Tone ; Auditory Threshold ; Child ; Child, Preschool ; Female ; Humans ; Male ; Speech Perception ; Vestibulocochlear Nerve Diseases ; physiopathology ; Young Adult
4.Influence on cell proliferation by small interfering RNA of Cyclin Y expression in laryngeal cancer cells.
Jun TAI ; Ai-Dong LI ; Yuan-Sheng RAO ; Yu-Bei HUANG ; Zhi-Gang HUANG ; Zhen-Kun YU ; Xiao-Hong CHEN ; Wei-Guo ZHOU ; Xiao XIAO ; Shen WANG ; Yang HAN ; Qiao-Yin LIU ; Ju-Gao FANG ; Xin NI
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2013;48(9):761-764
OBJECTIVEThe effects of lentivirus-mediated suppression of Cyclin Y (CCNY) expression on the proliferation of laryngeal cancer cells were investigated in vitro.
METHODSThe lentivirus vectors containing a small hairpin RNA (shRNA) to target CCNY were constructed.Hep-2 cells were divided into the following two experimental groups:the negative control group (control lentivirus infected cells) and CCNY knockdown group (CCNY shRNA-expressing lentivirus infected cells). After Hep-2 cells were infected, Real-time PCR was used to measure CCNY expression. The influence of CCNY on the proliferation of laryngeal cancer cells were assessed using MTT and colony formation experiments.Each experiment was performed in triplicate and repeated three times.
RESULTSLentiviruses expressing shRNA against CCNY were constructed and Hep-2 cells were infected with above mentioned lentivirus at MOI (Multiplicity of infection) of 120.Real-time PCR analysis showed that the mRNA expression of CCNY in Hep-2 cells in the knockdown group was significantly decreased (P < 0.05); the mRNA level of CCNY was 75.3% lower in the si-CCNY group than in the si-CTRL group. After 5 days of lentiviral infection, the cell viability was significantly lower in cells infected with the CCNY-shRNA lentivirus compared to cells infected with the control lentivirus following a 6-day incubation. The colony number was decreased by 60% in Hep-2 cells infected with the CCNY-shRNA-lentivirus infected cells following a 10-day incubation.
CONCLUSIONSThe results suggested that lentivirus-mediated downregulation of CCNY expression decreased the proliferation and growth potency of laryngeal cancer cells.Lentiviruses delivering shRNA against CCNY may be a promising tool for laryngeal cancer therapy.
Cell Line, Tumor ; Cell Proliferation ; Cyclins ; Humans ; Laryngeal Neoplasms ; metabolism ; Lentivirus ; genetics ; RNA, Small Interfering ; genetics
5.Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen.
Li-Qin SUN ; Jia-Ye LIU ; Yun HE ; Yang ZHOU ; Liu-Mei XU ; Lu-Kun ZHANG ; Fang ZHAO ; Xiao-Ning LIU ; Ying SONG ; Ting-Zhi CAO ; Yi-Mei TIAN ; Man RAO ; Hui WANG
Chinese Medical Journal 2020;133(23):2808-2815
BACKGROUND:
Lipid abnormalities are prevalent among people living with human immunodeficiency virus (HIV) (PLWH) and contribute to increasing risk of cardiovascular events. This study aims to investigate the incidence of dyslipidemia and its risk factors in PLWH after receiving different first-line free antiretroviral regimens.
METHODS:
PLWH who sought care at the Third People's Hospital of Shenzhen from January 2014 to December 2018 were included, and the baseline characteristics and clinical data during the follow-up were collected, including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). The risk factors of dyslipidemia after antiretroviral therapy were analyzed with the generalized estimating equation model.
RESULTS:
Among the 7623 PLWH included, the mean levels of TC, HDL-C and LDL-C were 4.23 ± 0.85 mmol/L, 1.27 ± 0.29 mmol/L and 2.54 ± 0.65 mmol/L, respectively, and the median TG was 1.17 (IQR: 0.85-1.68) mmol/L. Compared with that in PLWH receiving tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + ritonavir-boosted lopinavir (LPV/r), zidovudine (AZT) + 3TC + efavirenz (EFV), and AZT + 3TC + LPV/r, the incidence of dyslipidemia was lower in PLWH receiving TDF + 3TC + EFV. In multivariate analysis, we found that the risks of elevations of TG, TC, and LDL-C were higher with TDF + 3TC + LPV/r (TG: odds ratio [OR] = 2.82, 95% confidence interval [CI]: 2.55-3.11, P < 0.001; TC: OR = 1.24, 95% CI: 1.14-1.35, P < 0.001; LDL: OR = 1.06, 95% CI: 1.00-1.12, P = 0.041), AZT + 3TC + EFV (TG: OR = 1.41, 95% CI: 1.28-1.55, P < 0.001; TC: OR = 1.43, 95% CI: 1.31-1.56, P < 0.001; LDL: OR = 1.18, 95% CI: 1.12-1.25, P < 0.001), and AZT + 3TC + LPV/r (TG: OR = 3.08, 95% CI: 2.65-3.59, P < 0.001; TC: OR = 2.40, 95% CI: 1.96-2.94, P < 0.001; LDL: OR = 1.52, 95% CI: 1.37-1.69, P < 0.001) than with TDF + 3TC + EFV, while treatment with TDF + 3TC + LPV/r was less likely to restore HDL-C levels compared with TDF + 3TC + EFV (OR = 0.95, 95% CI: 0.92-0.97, P < 0.001). In addition to antiretroviral regimens, antiretroviral therapy duration, older age, overweight, obesity and other traditional factors were also important risk factors for dyslipidemia.
CONCLUSION
The incidence of dyslipidemia varies with different antiretroviral regimens, with TDF + 3TC + EFV having lower risk for dyslipidemia than the other first-line free antiretroviral regimens in China.
Aged
;
Anti-HIV Agents/adverse effects*
;
China/epidemiology*
;
Dyslipidemias/epidemiology*
;
HIV
;
HIV Infections/drug therapy*
;
Humans
;
Lamivudine/therapeutic use*
;
Lipids
;
Risk Factors